Physician

Tejaswi Rajasekhara Sastry, M.D.

According to 2025 Medicare claims, Tejaswi Sastry, M.D. (NPI: 1013005685) practices hematology/oncology in the Baltimore-Columbia-Towson, MD market, with the plurality of this provider's patient population coming from Howard, MD. This provider's primary affiliated billing organization is MARYLAND ONCOLOGY HEMATOLOGY P.A. (NPI: 1396710703; TIN: 113652573) and primary practice location at 21044-3257.

Sastry's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,090 traditional Medicare patients, billed 257,309 HCPCS/CPT codes, and received $4,189,053 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,245 prescription claims across 292 beneficiaries totaling $3,138,467 in drug costs, led by Revlimid (Lenalidomide). DME data shows 81 claims. Open Payments data shows 53 records totaling $32,151. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,164,989 to $4,189,053. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $720,446 to $3,138,467. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$2.1M$4.2M2015 Medicare payment: $1,164,989 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $1,682,448 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $2,443,759 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $2,876,008 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $3,107,061 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $3,662,475 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $3,595,994 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $3,327,757 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $3,263,751 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $4,189,053 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
201550197,418$1,164,989
2016823152,806$1,682,448
2017630182,209$2,443,759
2018805240,410$2,876,008
2019834241,858$3,107,061
2020730242,252$3,662,475
2021852282,617$3,595,994
2022886219,102$3,327,757
2023893237,988$3,263,751
20241,090257,309$4,189,053

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$1.6M$3.1M2015 Drug cost: $720,446 (USD; Tot_Drug_Cst)2016 Drug cost: $415,109 (USD; Tot_Drug_Cst)2017 Drug cost: $821,622 (USD; Tot_Drug_Cst)2018 Drug cost: $907,318 (USD; Tot_Drug_Cst)2019 Drug cost: $1,351,763 (USD; Tot_Drug_Cst)2020 Drug cost: $2,290,650 (USD; Tot_Drug_Cst)2021 Drug cost: $2,400,378 (USD; Tot_Drug_Cst)2022 Drug cost: $2,036,986 (USD; Tot_Drug_Cst)2023 Drug cost: $1,438,426 (USD; Tot_Drug_Cst)2024 Drug cost: $3,138,467 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015121562$720,446
2016116533$415,109
2017138695$821,622
2018155864$907,318
2019169778$1,351,763
2020186873$2,290,650
2021208979$2,400,378
2022208898$2,036,986
2023201853$1,438,426
20242921,245$3,138,467

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$38K$76K2015 Medicare payment: $16,201 (USD; DME_Suplr_Mdcr_Pymt_Amt)2018 Medicare payment: $63,297 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $76,012 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $3,845 (USD; DME_Suplr_Mdcr_Pymt_Amt)2021 Medicare payment: $5,936 (USD; DME_Suplr_Mdcr_Pymt_Amt)2022 Medicare payment: $2,598 (USD; DME_Suplr_Mdcr_Pymt_Amt)2023 Medicare payment: $12,272 (USD; DME_Suplr_Mdcr_Pymt_Amt)2024 Medicare payment: $1,938 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/R17$16,201
2016N/RN/RN/R
2017N/RN/RN/R
2018N/R172$63,297
2019N/R207$76,012
2020N/R60$3,845
2021N/R114$5,936
2022N/R92$2,598
2023N/R66$12,272
2024N/R81$1,938

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more278495$106
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more6991,152$73
80053Blood test, comprehensive group of blood chemicals6852,011$10
36415Insertion of needle into vein for collection of blood sample189247$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count7082,354$8

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
RevlimidLenalidomide36973$605,411
LenalidomideLenalidomide521,309$600,307
IbrancePalbociclib22616$343,597
VerzenioAbemaciclib13364$206,058
ErleadaApalutamide12360$128,848

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS CodeHCPCS DescriptionSupplier Rental IndicatorTotal Supplier BeneficiariesTotal Supplier ClaimsTotal Medicare Payment Amount
J8521Capecitabine, oral, 500 mgNN/R36$1,210
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodNN/R34$602
Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodNN/R11$125

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.50$1,961Novartis Pharmaceuticals Corporation
Research PaymentsReported research-related payment or transfer-of-value amount.3$30,190AstraZeneca Pharmaceuticals LP
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Tejaswi Rajasekhara Sastry, M.D.?

Tedicare shows public-source Medicare data for Tejaswi Rajasekhara Sastry, M.D. (NPI 1013005685), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Tejaswi Rajasekhara Sastry, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Tejaswi Rajasekhara Sastry, M.D.?

Tejaswi Rajasekhara Sastry, M.D. is linked to MARYLAND ONCOLOGY HEMATOLOGY P.A. (billing NPI 1396710703) in the available physician profile data.

Does Tejaswi Rajasekhara Sastry, M.D. have Open Payments data?

Tejaswi Rajasekhara Sastry, M.D. has 53 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.